---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-003268"
form_type: "8-K"
ticker: "DSS"
cik: "0000771999"
company_name: "DSS, INC."
filed_at: "2024-01-22T23:59:59+00:00"
generated_at: "2026-06-06T20:51:08.937364+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# DSS amends $12.86M promissory note with Impact BioMedical, extends maturity to 2030

## Summary
- Principal balance funded to $12,859,328.60, including $1,231,483.14 interest funding advanced Jan 17, 2024.
- Maturity extended to September 30, 2030; interest-only payments through Jan 2026, then monthly $126,380.80.
- Interest rate set at WSJ Prime + 0.50% (initial 9.00%); secured by blanket first lien on all Impact assets including patents.
- DSS is the lender and majority shareholder of Impact BioMedical, indicating continued related-party support.

## SEC filing metadata
- accession: 0001493152-24-003268
- form_type: 8-K
- ticker: DSS
- cik: 0000771999
- company_name: DSS, INC.
- filed_at: 2024-01-22T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/771999/000149315224003268/0001493152-24-003268-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/771999/000149315224003268/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-003268
- JSON: https://secwatch.observer/filing/0001493152-24-003268.json
- Plain text: https://secwatch.observer/filing/0001493152-24-003268.txt

## Key facts
- Material Agreements
  DSS, INC. amended Amendment with Impact BioMedical, Inc. valued at $859,328.60 (effective 2024-01-18).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Impact BioMedical, Inc.
  - Value: $859,328.60
  - Effective: 2024-01-18
  source text: Effective January 18, 2024, DSS, Inc. (the “Company”) and Impact BioMedical, Inc., a Nevada corporation (“Impact”) entered into an amendment to the revolving promissory note dated March 1, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/771999/000149315224003268/0001493152-24-003268-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.